Robert Luo

Title: The Innovative Contributions of Robert Luo

Introduction

Robert Luo is a distinguished inventor based in New City, NY (US). He has made significant contributions to the field of biotherapeutics, particularly in the development of novel compounds targeting KRAS mutations. With a total of three patents to his name, Luo's work is paving the way for advancements in cancer treatment.

Latest Patents

Luo's latest patents include "Glutarimide-containing pan-KRAS-mutant degrader compounds and uses thereof" and "Glutarimide-containing KRAS-mutant degrader compounds and uses thereof." The first patent discloses novel pan-KRAS glutarimide-containing compounds that exhibit KRAS degradation activities. These compounds are formulated into pharmaceutical compositions aimed at preventing and treating various diseases and conditions. The second patent focuses on glutarimide-containing compounds specifically designed for degrading the mutant form of KRAS, also with applications in pharmaceutical compositions for disease prevention and treatment.

Career Highlights

Robert Luo is currently employed at Tiger Biotherapeutics Inc., where he continues to innovate and develop therapeutic solutions. His work is characterized by a strong focus on addressing unmet medical needs through cutting-edge research and development.

Collaborations

Luo collaborates with talented colleagues, including Pin Huang and Jie Su, who contribute to the dynamic research environment at Tiger Biotherapeutics Inc. Their combined expertise enhances the potential for groundbreaking discoveries in the field of biotherapeutics.

Conclusion

Robert Luo's innovative work in developing KRAS-targeting compounds exemplifies the impact of dedicated inventors in the medical field. His contributions are crucial for advancing treatment options for patients with KRAS mutations.